Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-gamma production, thereby activating natural killer cell function. Monalizum
CAS Number:
[1228763-95-8]
Target:
IFNAR|||Chk
* VAT and and shipping costs not included. Errors and price changes excepted